High-Density Lipoprotein As a Therapeutic Target: Clinical Evidence and Treatment Strategies

This publication has 74 references indexed in Scilit:

• High-Density Lipoprotein and Cardiovascular Risk
  Circulation, 2004
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR * Trial)
  Published by Elsevier ,2003
• Expression Cloning and Characterization of a Novel Glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding Protein, GPI-HBP1
  Journal of Biological Chemistry, 2003
• Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia
  The American Journal of Cardiology, 2002
• Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids
  Journal of Biological Chemistry, 2001
• Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I
  Journal of Clinical Investigation, 2001
• Regulatory Effects of HDL on Smooth Muscle Cell Prostacyclin Release
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1999
• Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.
  The American Journal of Cardiology, 1998
• Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease
  Journal of the American College of Cardiology, 1992
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987